EP3538078A4 - Formulierungen zur effizienten verabreichung von cannabinoiden - Google Patents

Formulierungen zur effizienten verabreichung von cannabinoiden Download PDF

Info

Publication number
EP3538078A4
EP3538078A4 EP17869632.4A EP17869632A EP3538078A4 EP 3538078 A4 EP3538078 A4 EP 3538078A4 EP 17869632 A EP17869632 A EP 17869632A EP 3538078 A4 EP3538078 A4 EP 3538078A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
formulations
efficient delivery
delivery
efficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17869632.4A
Other languages
English (en)
French (fr)
Other versions
EP3538078A1 (de
Inventor
Benjamin F. Ross
Jerry B. Gin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gin Jerry B
Bennes Inc
Original Assignee
Gin Jerry B
Bennes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gin Jerry B, Bennes Inc filed Critical Gin Jerry B
Publication of EP3538078A1 publication Critical patent/EP3538078A1/de
Publication of EP3538078A4 publication Critical patent/EP3538078A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Physiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17869632.4A 2016-11-11 2017-11-11 Formulierungen zur effizienten verabreichung von cannabinoiden Withdrawn EP3538078A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662420981P 2016-11-11 2016-11-11
PCT/US2017/061202 WO2018089863A1 (en) 2016-11-11 2017-11-11 Formulations for efficient delivery of cannabinoids

Publications (2)

Publication Number Publication Date
EP3538078A1 EP3538078A1 (de) 2019-09-18
EP3538078A4 true EP3538078A4 (de) 2020-07-08

Family

ID=62110287

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17869632.4A Withdrawn EP3538078A4 (de) 2016-11-11 2017-11-11 Formulierungen zur effizienten verabreichung von cannabinoiden

Country Status (3)

Country Link
EP (1) EP3538078A4 (de)
CA (1) CA3046638A1 (de)
WO (1) WO2018089863A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
EP3745884A1 (de) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hanfpulver
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US20200061023A1 (en) * 2018-08-27 2020-02-27 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
CN108703963B (zh) * 2018-07-02 2023-04-14 宁夏医科大学 茴香脑在制备治疗神经病理性疼痛药物中的用途
WO2020010454A1 (en) * 2018-07-10 2020-01-16 Beleave Inc. Formulation of cannabinoid compounds
MX2021001333A (es) * 2018-08-07 2021-06-23 Ilylt Llc Composiciones y metodos para tratar disfuncion sexual y aumentar la respuesta y placer sexual.
EP3864000A4 (de) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthese von cannabigerol
CN109758450B (zh) * 2019-03-06 2021-01-29 天津医科大学 一种抗肿瘤新化合物、及其制备方法和用途
US20200323935A1 (en) * 2019-04-10 2020-10-15 G.I. Pharmaceuticals, Inc. dba E2BIO CONSULTANTS, INC. Novel method for the treatment of dyspepsia, food and medicine intolerances, irritable bowel syndrome and other functional gastrointestinal conditions
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
CA3040532C (en) * 2019-04-17 2021-12-21 Medcan Pharma A/S Lozenge for improved delivery of cannabinoids
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US20210251950A1 (en) * 2019-07-08 2021-08-19 Aaron Miles System and Method for Incorporating CBD/THC Cannabinoid Nanoparticle Carrier Compositions into Particulate Foods and Food Additives
US20210038513A1 (en) * 2019-08-09 2021-02-11 Jupiter Wellness, Inc. Cbd formulations and uses thereof
WO2021195540A1 (en) * 2020-03-26 2021-09-30 Radient Technologies Innovations Inc. Cannabinoid based composition for mitigation of viral effects
EP4304558A1 (de) * 2021-03-09 2024-01-17 Nutrition & Biosciences USA 1, LLC Oleogelzusammensetzung mit ethylcellulose und öligem wirkstoff
WO2023114529A2 (en) * 2021-12-17 2023-06-22 Bennes, Inc. Pharmacoactive formulations for delivery of psychedelic compounds
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060039959A1 (en) * 2002-06-14 2006-02-23 Werner Wessling Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
WO2015200864A1 (en) * 2014-06-27 2015-12-30 Crowley Kenton L Buccal and sublingual cannabinoid formulations and method of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
JP5704925B2 (ja) * 2008-02-08 2015-04-22 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−カンナビノイドコンジュゲート
US9186386B2 (en) * 2014-04-17 2015-11-17 Gary J. Speier Pharmaceutical composition and method of manufacturing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257463A1 (en) * 2002-05-31 2006-11-16 University Of Mississippi Transmucosal delivery of cannabinoids
US20060039959A1 (en) * 2002-06-14 2006-02-23 Werner Wessling Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents
WO2015200864A1 (en) * 2014-06-27 2015-12-30 Crowley Kenton L Buccal and sublingual cannabinoid formulations and method of making the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018089863A1 *

Also Published As

Publication number Publication date
EP3538078A1 (de) 2019-09-18
WO2018089863A1 (en) 2018-05-17
CA3046638A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
EP3538078A4 (de) Formulierungen zur effizienten verabreichung von cannabinoiden
EP3148589A4 (de) Stabile cannabinoidformulierungen
EP3273944A4 (de) Zusammensetzungen und verfahren zur abgabe von biomakromolekülwirkstoffen
EP3313394A4 (de) Antimikrobielle zusammensetzungen mit cannabinoiden
EP3346997A4 (de) Bioorthogonale zusammensetzungen
EP3302426A4 (de) D2o-stabilisierte pharmazeutische formulierungen
EP3102190A4 (de) Neuartige pharmazeutische formulierungen
EP3179856A4 (de) Transdermales cannabinoid-formulierungen
EP3509581A4 (de) Formulierungen von (r
EP3302437B8 (de) Stabile cannabinoidformulierungen
EP3253382A4 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP3096759A4 (de) Formulierungen aus pridopidin mit modifizierter freisetzung
EP3280421A4 (de) Pharmazeutische zusammensetzungen für eine kombinationstherapie
EP3160448A4 (de) Liposomale formulierungen zur freisetzung von nukleinsäuren
EP3523274A4 (de) Formulierungen zur verabreichung von eflornithin
EP3462885A4 (de) Stabile cannabinoidformulierungen
EP3541385A4 (de) Pharmazeutische formulierungen
PL3139904T3 (pl) Formulacja witaminy rozpuszczalnej w tłuszczach
EP3344232A4 (de) Mizellen für mukoadhäsive wirkstofffreisetzung
EP3177286A4 (de) Zusammensetzungen und verfahren zur physiologischen freisetzung von cannabidiol
EP3174525A4 (de) Formulierungen für das ohr zur behandlung von cerumen obturans
EP3265059A4 (de) Liposomale pharmazeutische kombinationsformulierungen
EP3102216A4 (de) Formulierungen zur mikropartikelförmigen freisetzung von zinkprotoporphyrinen
EP3454847A4 (de) Verbesserte arzneimittelformulierungen
EP3253391A4 (de) Wässrige formulierungen von vancomycin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200609

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/05 20060101ALI20200603BHEP

Ipc: A61K 9/00 20060101AFI20200603BHEP

Ipc: A61K 47/38 20060101ALI20200603BHEP

Ipc: A61P 25/00 20060101ALI20200603BHEP

Ipc: A61K 31/352 20060101ALI20200603BHEP

Ipc: A61K 36/185 20060101ALI20200603BHEP

Ipc: A61P 25/06 20060101ALI20200603BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220222